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Abstract
Background: Typhoid fever causes more than 21 million cases of disease and 200,000 deaths yearly worldwide, with more
than 90% of the disease burden being reported from Asia. Epidemiological data show high disease incidence in young
children and suggest that immunization programs should target children below two years of age: this is not possible with
available vaccines. The Novartis Vaccines Institute for Global Health developed a conjugate vaccine (Vi-CRM197) for infant
vaccination concomitantly with EPI vaccines, either starting at 6 weeks with DTP or at 9 months with measles vaccine. We
report the results from a Phase 1 and a Phase 2 dose ranging trial with Vi-CRM197 in European adults.
Methodology: Following randomized blinded comparison of single vaccination with either Vi-CRM197 or licensed
polysaccharide vaccines (both containing 25?0 mg of Vi antigen), a randomised observer blinded dose ranging trial was
performed in the same center to compare three concentrations of Vi-CRM197 (1?25 mg, 5?0 mg and 12?5 mg of Vi antigen)
with the polysaccharide vaccine.
Principal Findings: All vaccines were well tolerated. Compared to the polysaccharide vaccine, Vi-CRM197 induced a higher
incidence of mild to moderate short lasting local pain. All Vi-CRM197 formulations induced higher Vi antibody levels
compared to licensed control, with clear dose response relationship.
Conclusions: Vi-CRM197 did not elicit safety concerns, was highly immunogenic and is therefore suitable for further clinical
testing in endemic populations of South Asia.
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Introduction
Typhoid fever, a disease caused by Salmonella enterica serovar
Typhi (S. Typhi), represents a global public health issue causing
over 21 million cases of disease and over 200,000 deaths per year
worldwide [1]. Although endemic in many developing countries,
typhoid fever has the highest incidence in the Indian subcontinent
where 90% of the S. Typhi related morbidity and mortality are
reported [1,2]. Typhoid fever was previously considered a typical
disease of school children and adolescents [3]; however, most
recent epidemiologic data from India, Pakistan, Bangladesh and
Vietnam clearly show that younger children are also highly
affected by typhoid fever and are at risk of severe disease [3–7].
These data have prompted a re-consideration of prevention
strategies and suggest that immunization of subjects below two
years could be a better approach to protect young children, to
increase vaccination coverage and to reduce costs by concomitant
delivery with routine vaccines of the Expanded Program on
Immunization (EPI) [8–10].
Currently available typhoid vaccines, although moderately
effective and well tolerated, cannot be administered to children
younger than two years. Additionally, the Vi polysaccharide
induces a short lasting protection and requires repeated boosters
which might cause hypo-responsiveness [11]. Since S. Typhi is an
obligate human pathogen, an effective vaccination program could
lead to substantial herd protection [12]. Therefore, new highly
efficacious vaccines are needed to have the greatest public health
impact in high risk areas and to allow their use in existing EPI
vaccination programs. As shown by clinical results with the Vi-
rEPA vaccine in Vietnam [13–15], a conjugate Vi vaccine appears
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Vietnam have allowed the establishment of a serological threshold
for clinical protection [13].
The Novartis Vaccines Institute for Global Health (NVGH) was
founded in 2007 with the not for profit mission of developing
effective and affordable vaccines for neglected infectious diseases
of impoverished communities of developing countries [16]. By
conjugation of the Vi polysaccharide with the CRM197 protein,
NVGH developed a vaccine against typhoid fever (Vi-CRM197)
that has the potential to induce a T-cell dependent immunological
memory and to be effectively used for infant immunization in
developing countries [17–19].
We describe results from a Phase 1 trial and a subsequent Phase
2 dose ranging trial aimed to evaluate the clinical profile of Vi-
CRM197 in European adults and to select the dose for further




Vi-CRM197 contained purified Vi polysaccharide, derived from
Citrobacter, chemically conjugated to mutant diphtheria toxin
carrier protein, CRM197, widely used as carrier protein for several
conjugate vaccines [17–19].
The vaccine clinical lot (VI-10-001), available in single dose
vials, contained 25 mg of Vi antigen conjugated to CRM197 in
0.5 mL of injectable solution and did not contain any adjuvant,
stabilizer or preservative.
Study design
Phase 1 and 2 studies were designed as randomised controlled
trials and were conducted sequentially at the Center for the
Evaluation of Vaccination of the University of Antwerp (Antwerp,
Belgium) from May to November 2010.
Healthy adults aged 18 to 40 years were enrolled in both studies.
Subjects were excluded from the trial if they presented with serious
chronic or progressive disease, with immune dysfunction, under
immunosuppressive therapy, with bleeding diathesis, with hyper-
sensitivity to vaccine components, with progressive or severe
neurological disorder, with seizures or Guillain-Barre ´ syndrome,
with malignancy or lymphoproliferative disorder, that previously
received vaccines against typhoid fever, with previous history of
infection with S. Typhi, that received blood products, with body
temperature $38.0uC within 3 days of study vaccination. Women
who were pregnant or breast-feeding and women of childbearing
age not willing to use acceptable birth control measures were also
excluded. Ethical approval was obtained from the Ethical
Committee of the University Hospital of Antwerp. The studies
were conducted according with the International Conference on
Harmonization, Good Clinical Practice guidelines (ICH-GCP). All
participants provided written informed consent.
In Phase 1, Vi-CRM197 vaccine was administered as single
0.5 mL dose containing 25 mg of Vi antigen. Subsequent to the
Phase 1 study, with the objective to define the optimal Vi-CRM197
concentration for further development, the Phase 2 dose ranging
trial was implemented, using three different concentrations
administered as single 0.5 mL doses containing 1.25 mg, 5.0 mg
and 12.5 mg of Vi respectively; the formulations were obtained by
bedside dilution of the 25 mg vaccine with appropriate amount of
saline solution. In both studies the control vaccine was a licensed
Vi polysaccharide (Vi-PS) vaccine (TypherixH, GlaxoSmithKline)
containing 25 mg of Vi.
In the Phase 1 study, 50 subjects were randomized, with a 1:1
ratio using a randomization block size of four, to receive either Vi-
CRM197 25 mg or Vi-PS as a single intramuscular (IM) injection in
the deltoid of the non-dominant arm. In the Phase 2 study, 88
subjects were randomized, with a 1:1:1:1 ratio using randomiza-
tion block size of four, to receive a single IM dose of one of three
Vi-CRM197 concentrations (1.25 mg, 5.0 mg and 12.5 mgo fV i
respectively) or the Vi-PS. In both studies, randomization
sequence was computer generated by the sponsor. Assignment of
subject to treatment group was performed by designated
unblinded clinical site personnel by means of individual envelopes
provided by the sponsor who also established ad hoc monitoring
visits during both trials to ensure appropriateness of all protocol
procedures. The protocols for the two trials and supporting
CONSORT checklist are available as supporting information; See
Checklist S1, Protocol S1 and Protocol S2.
Evaluation of immunogenicity
Blood samples of 20 mL were obtained for hematological and
hematochemical analyses (Phase 1 only) prior to vaccination (day
1) and 28 days post vaccination. For both studies, urine samples
were obtained prior to vaccination to evaluate potential drug
abuse; additionally, urine pregnancy tests were performed in
females before vaccination and at the study end. Blood samples of
10 mL were obtained from both Phase 1 and Phase 2 subjects on
days 1, 28, and on day 180 in Phase 1 only. Blood samples were
centrifuged within 24 hours and serum was maintained below
220uC.
Antibody levels were measured by an enzyme-linked immu-
nossorbent assay (ELISA) in the Novartis Vaccines & Diagnostics
human serology laboratory (Marburg, Germany), using Vi
polysaccharide from Citrobacter. Round bottom 96-well microtiter
plates were coated overnight with 1.0 mg/mL Vi in PBS pH 7.0,
plates were blocked with 5% skim milk powder in PBS, then
duplicate samples of human sera, serially diluted 2-fold, were
added and incubated for 2 hours at room temperature. Goat anti-
human IgG (c-chain specific) conjugated to alkaline phosphatase
was added and incubated 2 hours at room temperature. After
30 min incubation with p-nitrophenyl-phosphate solution, the
reaction was stopped. The absorbance at 405 nm and 650 nm was
read. The A405–A650 were used as the test parameter.
Each plate contained a serially diluted pool of anti-Vi human
sera. This pool was assigned a value of 115.4 ELISA U/mL. A
standard curve was generated from the corresponding values using
a 4 parameter fit. ELISA units in test sera were calculated from
this curve. Low and high human serum controls were included on
each plate. The ELISA lower detection limit ranged from 3.0 to
7.8 U/mL.
Evaluation of safety
Safety of study vaccines was assessed by evaluation of solicited
indicators of reactogenicity within 7 days after vaccination.
Following vaccination, subjects were observed at the site for at
least 30 minutes. Subjects maintained a daily diary card for 7 days
post-vaccination recording local reactions (pain, induration,
erythema), systemic reactions (headache, malaise, chills, myalgia,
arthralgia, fatigue), body temperature (fever defined as axillary
temperature $38.0uC) and use of analgesic and antipyretic drugs.
Local pain and systemic reactions were scored by severity (mild,
moderate and severe) and erythema and induration by the
maximum diameter per day. All adverse events (AEs) were
recorded for 28 days post-vaccination, while all serious adverse
events (SAEs) were assessed and recorded for the entire study
duration. For consistent measurement of reactions, subjects were
Vi-CRM197 Conjugate Vaccine against Typhoid Fever
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temperature and with a plastic ruler for measurement of size of
local reactions.
Statistical methods
No statistical null hypothesis was associated with immunoge-
nicity or safety objectives. In the Phase 1 study with 25 subjects per
group, there was a 90% probability of observing at least 1 subject
with an adverse event if the true rate of such an event was 8.7%. In
the Phase 2 study with 20 subjects per vaccine group, there was a
90% probability of observing at least 1 subject with an adverse
event if the true rate of such an event was 10.9%.
All analyses were descriptive in nature. The pre-specified
primary population for immunogenicity analysis was the Modified
Intention to Treat Population (MITT). The MITT Population
included all subjects who received the vaccination, had at least one
post-vaccination blood sample collected, and at least one ELISA
result available.
Seroconversion was defined as a post vaccination increase of at
least four times the pre-vaccination antibody concentration.
Geometric mean concentrations (GMCs) and associated two-
sided 95% confidence intervals (CIs) were calculated by expo-
nentiating (base 10) the means of log-transformed (base 10) titers
and their 95% confidence intervals. Antibody concentrations
below assay limit of detection were assigned a value of one half of
the cut-off. At each sampling time GMCs of antibodies (with two-
sided 95% CIs) and reverse cumulative curves were calculated.
The percentages of subjects with seroconversion were calculated
for each vaccine group in each study. Analyses were performed
using SAS version 9.1 (SAS Institute Inc, Cary, North Carolina).
Results
A total of 138 subjects were enrolled across both studies (50
Phase 1; 88 Phase 2), of whom 133 (96%) completed the studies
[47 (94%) Phase 1; 86 (98%) Phase 2]. There were no withdrawals
from either study due to AEs (figure 1). Demographic character-
istics were similar among vaccine groups and between the two
studies (table 1). None of the subjects showed clinically significant
variations of haematological and hematochemical parameters after
vaccination (day 28) compared to pre-vaccination values. The
most frequently reported local reaction was mild to moderate local
pain, which occurred with a similar frequency among all four Vi-
CRM197 groups and was consistently higher in Vi-CRM197 groups
compared with Vi-PS control groups. Percentages of subjects
reporting pain did not show a dose dependent relation in the Vi-
CRM197 groups. One subject in each of the four Vi-CRM197
groups reported severe pain lasting ,1 day; no severe cases of
erythema and induration were reported (table 2). Percentages of
subjects reporting systemic reactions were similar among all
vaccine groups. Headache and fatigue were the most commonly
reported systemic reactions in all vaccine groups (overall range was
27% to 48% and 24% to 50% for headache and fatigue
respectively). Severe systemic reactions were uncommon and were
reported by seven subjects overall (one case in the Vi-CRM197
25 mg group and six in Vi-PS group) (table 1). No differences were
observed in the use of analgesic or antipyretic drugs among study
groups (table 2). Of all study subjects, 59% of the Vi-CRM197 and
53% of the Vi-PS recipients reported at least one AE during the
28 days after vaccination and 38% and 26% of these were
considered possibly or probably related to the study vaccine, in the
Figure 1. Subject Completion Flow Chart.
doi:10.1371/journal.pone.0025398.g001
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or probably related AEs were reported from day 29 to day 180.
Most of the AEs reported in both studies were mild or moderate in
nature. The percentage of subjects reporting any AEs or AEs
possibly or probably vaccine related was lower in Phase 1 than in
Phase 2 (table 3). Two unrelated SAEs were reported in Phase 1
Table 1. Baseline demographic characteristics by vaccine group.
Phase 1 Phase 2
Vi-PS
Vi-CRM197






1.25 mg Vi-PS All
n=25 n=25 n=50 n=22 n=22 n=22 n=22 n=88
Mean age (SD) 23.9 (4.6) 21.9 (2) 22.9 (3.7) 24.3 (4.9) 24.3 (5.4) 24 (5.7) 23.8 (5.5) 24.1 (5.3)
Number of women (%) 15 (60) 18 (72) 33 (66) 14 (64) 15 (68) 17 (77) 15 (68) 61 (69)
Ethnic origin, no. (%)
Caucasian 25 (100) 25 (100) 50 (100) 22 (100) 22 (100) 22 (100) 21 (95) 87 (99)
Black 0 0 0 0 0 0 1 (5) 1 (1)
Mean weight (SD) 72.5 (13.4) 71.9 (12.3) 72.2 (12.7) 70 (14.2) 70.1 (12.1) 69.2 (10.5) 70.7 (8.6) 70 (11.3)
Mean height (SD) 174.8 (8.3) 173.6 (9) 174.2 (8.6) 173.1 (9.6) 173.0 (9.9) 172.2 (7.3) 175.5 (7.0) 173.5 (8.5)
BMI 23.7 (4) 23.8 (2.9) 23.7 (3.4) 23.3 (3.9) 23.4 (3.5) 23.3 (3) 22.9 (2) 23.2 (3.2)
Note: BMI, Body Mass Index; SD, standard deviation.
doi:10.1371/journal.pone.0025398.t001
Table 2. Number (%) of Subjects Reporting Local and Systemic Reactions During Days 1 to 7.










n=25 n=25 n=21 n=22 n=22 n=22
Local reactions, no. (%) Severity
Erythema Any 1 (4) 4 (16) 3 (14) 2 (9) 2 (9) 0
.100 mm 0 0 0 0 0 0
Induration Any 1 (4) 7 (28) 3 (14) 4 (18) 3 (14) 2 (9)
.100 mm 0 0 0 0 0 0
Pain Any 9 (36) 21 (84) 17 (81) 16 (73) 20 (91) 8 (36)
Severe
* 0 1( 4 ) 1( 5 ) 1( 5 ) 1( 5 ) 0
Systemic reactions, no. (%)
Chills Any 0 1 (4) 1 (5) 2 (9) 2 (9) 2 (9)
Severe
* 00 0 00 0
Malaise Any 4 (16) 9 (36) 4 (19) 4 (18) 4 (18) 4 (18)
Severe
* 2 (8) 0 0 0 0 1 (5)
Myalgia Any 0 7 (28) 4 (19) 3 (14) 3 (14) 3 (14)
Severe
* 00 0 00 0
Arthralgia Any 0 1 (4) 2 (10) 0 0 0
Severe
* 00 0 00 0
Headache Any 8 (32) 9 (36) 10 (48) 9 (41) 9 (41) 6 (27)
Severe
* 1( 4 ) 1( 4 ) 0 0 0 0
Fatigue Any 6 (24) 12 (48) 7 (33) 11 (50) 8 (36) 7 (32)
Severe
* 2( 8 ) 0 0 0 0 0
Fever $38uC Any 0 0 0 0 0 0
$40uC0 0 0 0 0 0
Analgesic/Antipyretic Medication
Use
5 (20) 3 (12) 5 (25) 7 (27) 7 (32) 3 (14)
*Defined as unable to perform normal daily activity.
doi:10.1371/journal.pone.0025398.t002
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and one hospitalization for ankle fracture. No SAEs were reported
in the Phase 2 study. No AEs leading to premature withdrawal
from the study and no deaths were reported in both studies.
A total of 130 subjects had evaluable day 28 anti-Vi ELISA
results and were included in the immunogenicity analyses at day
28 post-vaccination. At baseline (day 1), a high percentage of the
sera (84%) had antibody levels below limit of detection. These sera
were assigned values half the detection level and thus the
calculated GMCs, which were similar in all the six vaccine
groups, reflect the assigned values (table 4). The GMCs at day 28
of the four Vi-CRM197 groups were higher (range from 63 to 304)
than the licensed Vi-PS vaccine groups (range from 37 to 52)
(Table 3). Day 28 GMCs in the Vi-CRM197 groups were dose
dependent; the highest Vi-CRM197 dose (25 mg) elicited the
highest antibody level (304) and the lowest level (63) was observed
for the Vi-CRM197 1.25 mg dose. These findings are further
illustrated by reverse cumulative distribution curves for anti-Vi
ELISA concentrations (figure 2). Four weeks after vaccination, at
least 95% of the subjects vaccinated with Vi-CRM197 achieved
seroconversion, whereas 88% and 95% of subjects achieved
seroconversion in the Vi-PS control groups. In the Phase 1 study,
six months after the vaccination (day 180), seroconversion rates
were still very high in both vaccine groups (95% and 92% in the
Vi-CRM197 25 mg and Vi-PS groups, respectively). However,
although the GMC of Vi-CRM197 25 mg group (69) was still
higher than that of Vi-PS (51), a faster decrease in antibody levels
compared to the control group was noticed (table 4).
Table 3. Number (%) of Subjects with Adverse Events During Days 1 to 28.
Phase 1 Phase 2
Vi-PS Vi-CRM197 25 mg Vi-CRM197 12.5 mg Vi-CRM197 5.0 mg Vi-CRM197 1.25 mg Vi-PS
n=25 n=25 n=21 n=22 n=22 n=22
Any AE 10 (40) 8 (32) 11 (52) 16 (73) 18 (82) 15 (68)
Vaccine-related AEs
* 3 (12) 6 (24) 5 (24) 11 (50) 12 (55) 9 (41)
AEs leading to discontinuation 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Any SAE 2 (8) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Vaccine-related SAEs
* 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Note:
*Determined by the investigator to be possibly or probably related to the study vaccine.
doi:10.1371/journal.pone.0025398.t003
Table 4. Immunogenicity Profile of NVGH Vi-CRM197 Conjugate Vaccine and Licensed Vi-PS Vaccine.
Phase 1 Phase 2








day 1 GMC 3.8 3.2 3.0 2.4 2.8 2.2
95% CI (2.7, 5.3) (2.3, 4.6) (2.4, 3.8) (1.9, 3.0) (2.2, 3.6) (1.7, 2.8)
N 2 5 2 4 2 12 1 1 92 0
day 28 GMC 52 304 192 111 63 37
95% CI (38, 71) (226, 411) (129, 286) (75, 165) (41, 95) (24, 55)
N 2 4 2 5 2 12 1 1 92 0
day 180 GMC 51 69 na na na na
95% CI (37, 69) (50, 94)
N2 4 2 3
Seroconversion
*
day 28 n (%) 21 (88) 23 (96) 21 (100) 21 (100) 18 (95) 19 (95)
95% CI (68, 97) (79, 100) (84, 100) (84, 100) (74, 100) (75, 100)
N 2 4 2 4 2 12 1 1 92 0
day 180 n (%) 22 (92) 21 (95) na na na na
95% CI (73, 99) (77, 100)
N2 4 2 2
*Number and percentage of subjects achieving at least a four-fold rise in ELISA antibody concentrations in the post-vaccination blood sample.
na: not applicable.
doi:10.1371/journal.pone.0025398.t004
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Epidemiological studies provide compelling evidence that
typhoid fever induces significant disease burden in Asia and that,
particularly in the urban slums of the Indian subcontinent, the
disease incidence is huge [1–2]. Additionally, the most recent data
do not support the previous belief that typhoid is a disease affecting
almost exclusively school children and adolescents [3]; in fact,
children aged less than two years are highly affected in India,
Pakistan and Bangladesh by clinically severe disease [3–6]. In
industrialized countries, typhoid control has been largely achieved
by provision of clean water, adequate sanitation and overall
improved hygiene conditions. Unfortunately these conditions are
only a long term solution for most of the developing countries
where the disease is endemic [6,8]. This public health issue is
further complicated by the increasing emergence of multi-drug
resistant strains of S.Typhi [6,8–9]. Resistance to antimicrobials
renders the control of the disease even more difficult and
expensive, as the easily available and cheaper first-line antibiotics
are not effective and their use leads to increased hospitalization
and associated costs [6,8,10]. Therefore, vaccine prevention
represents the only concrete option for efficient disease control.
After discontinuation of the highly reactogenic whole-cell S.
Typhi vaccine [6], effective and well tolerated vaccines, such as Vi
polysaccharide and live attenuated Ty21a vaccine, have been
developed. However, these vaccines have limitations; the Vi
polysaccharide vaccine cannot be administered to subjects
younger than 2 years and, even in pre-school children, its efficacy
is controversial [10]. Additionally, polysaccharide vaccines do not
induce immunological memory, require frequent boosters, to
maintain adequate protection, and may be associated with
hyporesponsiveness [11]. The commercially available formulation
of Ty21a vaccine can only be administered to children older than
6 years and requires three doses to induce protection. Conse-
quently the use of these vaccines and their impact on the control of
the disease in endemic countries has generally been very limited.
The development of new vaccines has been advocated to
overcome the limitations of the current ones and allow the use
of alternative vaccination strategies for younger children and
infants [6,8–9]. Although the National Institutes of Health (NIH)
pioneering work has shown that a prototype Vi conjugate vaccine
can be developed and is highly efficacious, there has not been a
sufficient commercial incentive for vaccine manufacturers to invest
in the development of improved typhoid vaccines for developing
countries.
NVGH, an institute created with the specific objective of
developing new and affordable vaccines against neglected diseases
for the impoverished populations of developing countries [16], has
developed a Vi conjugate vaccine which, in preclinical studies, has
shown to be safe and highly immunogenic [17–18].
The clinical studies described in this paper have shown that Vi-
CRM197 is clinically well tolerated. The only evidence of
reactogenicity was given by the higher incidence of pain at the
injection site compared to Vi-PS. Interestingly, the reaction rates
did not show a dose dependent relationship and were similar across
the four Vi-CRM197 concentrations tested. However, in most of the
cases, reported pain was mild to moderate and of short duration.
Additionally, pain was never associated with any evidence of
inflammation at the injection site, as shown by the very low rates of
erythema and induration, which were not different between the two
study vaccines. The use of analgesic medications in the conjugate
vaccine group was low and similar to that of the Vi-PS control
group; finally, no subject withdrew from the trial due to adverse
reactions. Systemic post immunization reactions were consistent
withaninjectable vaccine;theirratesweregenerallylowanddidnot
significantly differ among the various vaccine groups. Importantly,
no case of fever was reported, nor was any case of vaccine related
serious adverse event. Larger Phase 2–3 studies will help define
more precisely the safety profile of the vaccine, but the initial data
show that Vi-CRM197 is a safe vaccine.
The immunogenicity data show that the Vi-CRM197, even at
very low antigen concentrations (i.e., 1.25 mg/dose=1/20
th of the
Figure 2. Reverse Cumulative Curves of Anti-Vi ELISA Concentrations before (day 1) and four weeks (day 28) After Vaccination with
Vi-CRM197 or Vi-PS. Antibody concentrations are given in log scale. Values below the limit of detection of the assay were set to 1.0 U/mL.
doi:10.1371/journal.pone.0025398.g002
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(25 mg/dose) and the overall postimmunization Vi-CRM197 to Vi-
PS GMC ratio varies between 1.7 and 5.8. As shown by field trials
with the Vi-PS [20–21] and with the Vi-rEPA conjugate vaccine
[13], antibodies to the Vi antigen confer protection against
typhoid fever. Therefore, inferring the efficacy of the conjugate
vaccine based on immunogenicity data is scientifically justified and
demonstration that antibody levels induced by Vi-CRM197 in
infants are not less than those induced by the Vi-PS vaccine in
older children, a population where vaccine efficacy has been
shown, could be an appropriate basis for regulatory approval.
However, establishing a correlation with the immunogenicity of
the Vi-rEPA vaccine and, more importantly, with the serological
threshold of protection defined in the Vi-rEPA Vietnamese
efficacy trial [13] would be extremely valuable and is currently
underway.
The current data are very promising and suggest that an
effective conjugate vaccine against typhoid fever can be rapidly
developed. This vaccine has been primarily developed for
immunization of the impoverished populations of South Asia,
which have the highest risk of infection and severe disease.
Therefore, it is essential to evaluate its clinical profile in the
populations that will ultimately use the vaccine. To this purpose,
age de-escalation Phase 2 clinical trials with Vi-CRM197 are now
ongoing in South Asia.
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